Chemical formula: C₂₉H₃₁N₇O₃ Molecular mass: 525.613 g/mol
Selpercatinib is indicated for:
Population group: only adults (18 years old or older)
Selpercatinib as monotherapy is indicated for the treatment of adults with advanced RET fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adults (18 years old or older)
Selpercatinib as monotherapy is indicated for the treatment of adults with advanced RET fusion-positive thyroid cancer who require systemic therapy following prior treatment with sorafenib and/or lenvatinib.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)
Selpercatinib as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced RET-mutant medullary thyroid cancer (MTC).
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Selpercatinib is contraindicated in the following cases:
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
